JP2012501351A5 - - Google Patents

Download PDF

Info

Publication number
JP2012501351A5
JP2012501351A5 JP2011525283A JP2011525283A JP2012501351A5 JP 2012501351 A5 JP2012501351 A5 JP 2012501351A5 JP 2011525283 A JP2011525283 A JP 2011525283A JP 2011525283 A JP2011525283 A JP 2011525283A JP 2012501351 A5 JP2012501351 A5 JP 2012501351A5
Authority
JP
Japan
Prior art keywords
key
type
site
composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011525283A
Other languages
English (en)
Japanese (ja)
Other versions
JP5707326B2 (ja
JP2012501351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/055608 external-priority patent/WO2010027973A1/en
Publication of JP2012501351A publication Critical patent/JP2012501351A/ja
Publication of JP2012501351A5 publication Critical patent/JP2012501351A5/ja
Application granted granted Critical
Publication of JP5707326B2 publication Critical patent/JP5707326B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011525283A 2008-09-02 2009-09-01 ヒトパピローマウイルス/Ii−keyのハイブリッドおよびその使用方法 Expired - Fee Related JP5707326B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9360608P 2008-09-02 2008-09-02
US61/093,606 2008-09-02
US16990809P 2009-04-16 2009-04-16
US61/169,908 2009-04-16
PCT/US2009/055608 WO2010027973A1 (en) 2008-09-02 2009-09-01 Human papillomavirus / li-key hybrids and methods of use

Publications (3)

Publication Number Publication Date
JP2012501351A JP2012501351A (ja) 2012-01-19
JP2012501351A5 true JP2012501351A5 (enExample) 2012-10-18
JP5707326B2 JP5707326B2 (ja) 2015-04-30

Family

ID=41797447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011525283A Expired - Fee Related JP5707326B2 (ja) 2008-09-02 2009-09-01 ヒトパピローマウイルス/Ii−keyのハイブリッドおよびその使用方法

Country Status (5)

Country Link
US (1) US8748130B2 (enExample)
EP (1) EP2344191A4 (enExample)
JP (1) JP5707326B2 (enExample)
CA (1) CA2731444A1 (enExample)
WO (1) WO2010027973A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011125306A (ru) * 2008-11-21 2012-12-27 Юнивёрсити Оф Копенгаген Праймирование иммунного ответа
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
IL299348B2 (en) 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
TW202012430A (zh) * 2018-04-26 2020-04-01 美商艾吉納斯公司 熱休克蛋白質-結合之胜肽組成物及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9305435A (pt) * 1992-03-06 1994-12-27 Innogenetics Nv Processo para determinação de peptídeos correspondendo a epítopos imunologicamente importantes e seu uso em um processo para determinação de anticorpos ou peptídeos biotinilados correspondendo a epítopos imunologicamente importantes, processo para preparação dos mesmos e composições contendo os mesmos
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
DE69628731T3 (de) 1995-11-01 2012-09-20 Bracco Suisse S.A. Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel
WO1997049430A1 (en) 1996-06-26 1997-12-31 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6432409B1 (en) 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
DE60332377D1 (de) * 2002-10-21 2010-06-10 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
CN101795705A (zh) * 2007-05-31 2010-08-04 莱顿教学医院 皮内hpv肽接种
US7750588B2 (en) 2007-06-29 2010-07-06 Faurecia Automotive Seating Canada Limited Method of counting drive motor rotations, and memory modules, storage media, and motor and vehicle apparatuses utilizing same

Similar Documents

Publication Publication Date Title
CN111217917B (zh) 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
JP2008529558A5 (enExample)
JP2013501038A5 (enExample)
JP2015509707A5 (enExample)
EP3463444B1 (en) Improvement of hpv l2 peptide immunogenicity
JP2010529860A5 (enExample)
JP2019506175A5 (enExample)
JP2008505985A5 (enExample)
JP2012515557A5 (enExample)
US20250222094A1 (en) Polynucleotide molecules used for the prevention or treatment of hpv infection related diseases
JP2010506926A5 (enExample)
Gissmann et al. Therapeutic vaccines for human papillomaviruses
JP2012501351A5 (enExample)
CN101952320B (zh) 具有免疫原性的物质
JP2005512518A5 (enExample)
JP2008539164A5 (enExample)
CN113430178B (zh) 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
JP2011521648A5 (enExample)
JP2002516662A5 (enExample)
CN101880328A (zh) 微小隐孢子虫Th多表位基因和融合蛋白及其应用
US11547753B2 (en) Cutaneous papilloma virus vaccine
JP2014503174A5 (enExample)
JPWO2023034783A5 (enExample)
HK40006519A (en) Improvement of hpv l2 peptide immunogenicity
HK40006519B (en) Improvement of hpv l2 peptide immunogenicity